Capricor Therapeutics (CAPR) Operating Income (2010 - 2026)

Capricor Therapeutics' Operating Income history runs 17 years deep, the most recent figure standing at -$36.8 million for Q1 2026.

• On a quarterly basis, Operating Income fell 47.19% year-over-year to -$36.8 million in Q1 2026; TTM through Mar 2026 was -$119.9 million, a 109.38% decrease from a year earlier, with the FY2025 full-year figure at -$108.1 million, down 154.07% from the prior year.
• Operating Income slipped to -$36.8 million in Q1 2026 per CAPR's latest filing, from -$29.2 million in the prior quarter.
• Across five years, Operating Income topped out at -$1.3 million in Q4 2023 and bottomed at -$36.8 million in Q1 2026.
• The 5-year median for Operating Income is -$8.2 million (2023), against an average of -$14.2 million.
• Across the five-year window, Operating Income surged 84.12% in 2023 and sank 500.66% in 2024, its largest moves.
• Year by year, Operating Income stood at -$8.1 million in 2022, then jumped by 84.12% to -$1.3 million in 2023, then sank by 500.66% to -$7.7 million in 2024, then slumped by 278.83% to -$29.2 million in 2025, then declined by 26.12% to -$36.8 million in 2026.
• Per Business Quant, the three latest CAPR Operating Income figures stand at -$36.8 million (Q1 2026), -$29.2 million (Q4 2025), and -$26.3 million (Q3 2025).